NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Stock Now Rated “Hold” by Wall Street Analysts

Shares of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) have been given an average recommendation of “Hold” by the seven brokerages that are currently covering the company, MarketBeat reports. Two research analysts have rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $34.50.

A number of equities research analysts have issued reports on the stock. Wall Street Zen lowered shares of NRx Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Zacks Research downgraded shares of NRx Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Wednesday, August 26th. UBS Group reaffirmed a “buy” rating on shares of NRx Pharmaceuticals in a research report on Wednesday, August 26th. Weiss Ratings reiterated a “sell (d-)” rating on shares of NRx Pharmaceuticals in a research note on Wednesday, August 5th. Finally, HC Wainwright reiterated a “buy” rating on shares of NRx Pharmaceuticals in a report on Tuesday, August 25th.

Institutional Investors Weigh In On NRx Pharmaceuticals

A number of hedge funds have recently bought and sold shares of NRXP. Squarepoint Ops LLC purchased a new stake in shares of NRx Pharmaceuticals during the second quarter worth approximately $54,000. Ethos Financial Group LLC raised its holdings in NRx Pharmaceuticals by 33.6% in the first quarter. Ethos Financial Group LLC now owns 15,900 shares of the company’s stock valued at $34,000 after acquiring an additional 4,000 shares in the last quarter. Finally, AdvisorShares Investments LLC raised its holdings in NRx Pharmaceuticals by 28.2% in the first quarter. AdvisorShares Investments LLC now owns 420,467 shares of the company’s stock valued at $896,000 after acquiring an additional 92,463 shares in the last quarter. Institutional investors and hedge funds own 4.27% of the company’s stock.

NRx Pharmaceuticals Stock Performance

Shares of NRXP opened at $2.85 on Friday. The stock has a market capitalization of $123.41 million, a PE ratio of -5.18 and a beta of 2.07. NRx Pharmaceuticals has a 1 year low of $1.62 and a 1 year high of $5.05. The company’s 50-day simple moving average is $3.28 and its 200-day simple moving average is $3.34.

NRx Pharmaceuticals (NASDAQ:NRXP) last posted its quarterly earnings data on Friday, August 14th. The company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.33). The firm had revenue of $1.10 million for the quarter, compared to analyst estimates of $1.33 million. On average, sell-side analysts predict that NRx Pharmaceuticals will post -0.80 earnings per share for the current year.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc (NASDAQ: NRXP) is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders, with an emphasis on depression, suicidal ideation and other serious neuropsychiatric conditions. The company’s programs are investigational and are intended to address areas where available therapies may have limitations.

NRx’s lead program is NRX-101, an oral fixed-dose combination of D-cycloserine and lurasidone being developed for conditions including bipolar depression with acute suicidal ideation or behavior.